You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Mitochondrial Dysfunction in HAART: Point of Care Tests

    SBC: MITOSCIENCES, INC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust t ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Modulation of the Innate Immune System by Fisetin for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most prevalent age-associated disease and growing evidence suggeststhat aspects of the innate immune system play a major role its progression. Based on this evidence, we propose a new approach to the treatm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Multipurpose reversible terminators

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: NHGRI

    DESCRIPTION (provided by applicant): This Phase 2 STTR application will allow the Foundation for Applied Molecular Evolution (FfAME) to complete its transfer of technology to Firebird Biomolecular Sciences LLC, allowing Firebird to commercialize nucleoside triphosphates where the 3'-OH groups are blocked by a 3'-ONH2 group. Triphosphates having this modification are accepted by DNA polymerases and ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Nanoemulsion-based vaccine for chronic hepatitis B virus

    SBC: BLUEWILLOW BIOLOGICS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is the most common cause of chronic viral liver disease worldwide. More than 370 million people are chronically infected with HBV leading to nearly one million deaths annually as a result of cirrhosis, liver failure and hepatocellular carcinoma (HCC). Currently available therapies against chronic HBV are expensive, require long-term admi ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Nanofiber Expanded CD34+ Stem Cells for Osteoporosis Therapy

    SBC: HNB Therapeutics LLC            Topic: NIA

    Summary Glucocorticoid induced osteoporosis is the most common cause of secondary osteoporosisand the primary cause before ageIt affects overof the general populationwhereinare womenIn postmenopausal women and men agedand overtreatment would be recommended in at least half based on theAmerican College of Rheumatology guidelinesAdult stem cells are a promising class of regenerative cellssome lineag ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Nanoparticle scavengers for medical countermeasures against mycotoxin

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: NIGMS

    DESCRIPTION (provided by applicant): Mycotoxin is naturally occurring and is a toxic small molecule produced by fungi. These fungal toxins are representative of a large number of lipophilic agents that pose significant acute and chronic dangers to militarycombatants as potential warfare agents. There are many examples of mycotoxins, some more acutely potent than others. Mycotoxin is classified as ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Neuroprotective therapy of stroke with HUCNC and simvastatin

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated with a lower risk of graft-versus-host disease (GVHD), and UCBCs are younger than adult bone marrow st ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Neurorestorative therapy of stroke with HUCBC in T2DM rats

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Noregen(TM), a regenerative medicine ocular therapeutic

    SBC: Retinal Solutions LLC            Topic: NEI

    Project Summary Diabetic retinopathy and Retinal Vein OcclusionRVOaccount for most new cases of blindness in the United StatesThese diseases are marked by retinal swellingedemaand new leaky vessel formationneovascularizationtriggered by pathologically high concentrations of Vascular Endothelial Growth FactorVEGFThe primary treatment is VEGF blocking drugs to control the neovascularization and edem ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke

    SBC: BioTime, Inc.            Topic: 100

    ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading to excessive socioeconomic burdenCell therapy using primary MSCs has been actively explored by us and others as a therapeutic solution to this unmet medical needHoweversince the therapeutic efficacy of ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government